Ceftazidime Sodium In Plastic Container

ANDA 63221, held by Baxter Hlthcare. Ceftazidime Sodium.

As of Nov 15, 2026, ANDA 63221 (Ceftazidime Sodium In Plastic Container), held by Baxter Hlthcare, was first approved by FDA on Apr 29, 1993, with 3 approved supplements and 0 published complete response letters.

First approved: Apr 29, 1993
Supplements approved: 3
Complete response letters: 0

Approvals and New Uses

The original application and every efficacy supplement, newest first; all 4 submissions below

Date	Submission	Status	Documents
Apr 29, 1993	Original application	Approved	None posted

Products

3 strengths and forms


Ceftazidime Sodium In Plastic ContainerEQ 10MG BASE/ML · injectable;injection	Ceftazidime Sodium	Discontinued
Ceftazidime Sodium In Plastic ContainerEQ 20MG BASE/ML · injectable;injection	Ceftazidime Sodium	Discontinued
Ceftazidime Sodium In Plastic ContainerEQ 40MG BASE/ML · injectable;injection	Ceftazidime Sodium	Discontinued

All 4 submissions, including labeling and manufacturing supplements


Apr 26, 1995	Supplement 3Manufacturing	Approved	None posted
Jan 6, 1995	Supplement 2Manufacturing	Approved	None posted
Aug 29, 1994	Supplement 1Labeling	Approved	None posted
Apr 29, 1993	Original application	Approved	None posted

Identifiers

Application: ANDA 63221
Drugs@FDA: Overview at FDA
Company: Baxter Healthcare

Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters